ReviewInternational journal of molecular sciences2020
Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- MASLD and sarcopenia research (2012-2025): a multi-database bibliometric analysis.Frontiers in nutrition · 2026Pooled it
- Alterations in the Gut Microbiota of Cirrhotic Patients With Sarcopenia and PH After TIPS.Clinical and translational gastroenterology · 2026Article
- Sarcopenia as a Predictor of Mortality Among Cirrhotic Patients Awaiting Liver Transplantation.International journal of hepatology · 2026Article
- Sarcopenia and frailty: An in-depth analysis of the pathophysiology and effect on liver transplant candidates.World journal of hepatology · 2025Review
- The prognostic nutritional index is an effective prognostic and nutritional status indicator for cirrhosis.BMC gastroenterology · 2025Article
- The Role of Myokines in Liver Diseases.International journal of molecular sciences · 2025Review
- Pathophysiological-Based Nutritional Interventions in Cirrhotic Patients with Sarcopenic Obesity: A State-of-the-Art Narrative Review.Nutrients · 2024Review
- Article
- Analysis of intestinal flora in elderly Uygur patients with sarcopenia.Immunity, inflammation and disease · 2024Article
- Association of gut microbiota with portal vein pressure in patients with liver cirrhosis undergoing living donor liver transplantation.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- A novel imaging index for predicting adverse progression in acute-on-chronic liver failure related to hepatitis B virus: the low erector spine index.BMC gastroenterology · 2023Article
- Accounting Gut Microbiota as the Mediator of Beneficial Effects of Dietary (Poly)phenols on Skeletal Muscle in Aging.Nutrients · 2023Review
- The protective effect of IL-12/23 neutralizing antibody in sarcopenia associated with dextran sulfate sodium-induced experimental colitis.Journal of cachexia, sarcopenia and muscle · 2023Article
- Sarcopenia in Chronic Liver Disease: A Metabolic Perspective.Journal of clinical and translational hepatology · 2022Review
- Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis.International journal of molecular medicine · 2022Article
- Gut dysbiosis and body composition in cirrhosis.World journal of hepatology · 2022Article
- Inflammatory Bowel Disease and Sarcopenia: Its Mechanism and Clinical Importance.Journal of clinical medicine · 2021Review
- Comparison of SARC-F Score among Gastrointestinal Diseases.Journal of clinical medicine · 2021Article
- Muscular abnormalities in liver cirrhosis.World journal of gastroenterology · 2021Review
- Dynapenia Rather Than Sarcopenia Is Associated with Metabolic Syndrome in Patients with Chronic Liver Diseases.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia in patients with liver cirrhosis (LC) has been attracting much attention these days because of the close linkage to adverse outcomes. LC can be related to secondary sarcopenia due to protein metabolic disorders and energy metabolic disorders. LC is associated with profound alterations in gut microbiota and injuries at the different levels of defensive mechanisms of the intestinal barrier. Dysbiosis refers to a state in which the diversity of gut microbiota is decreased by decreasing the bacterial species and the number of bacteria that compose the gut microbiota. The severe disturbance of intestinal barrier in LC can result in dysbiosis, several bacterial infections, LC-related complications, and sarcopenia. Here in this review, we will summarize the current knowledge of the relationship between sarcopenia and dysbiosis in patients with LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.